Nurix Therapeutics Pipeline Review: BTK Degraders and Targeted Protein Degradation Advance in B-Cell Malignancies
Key Insights
Nurix Therapeutics is advancing NX-5948, an oral BTK (search) degrader, in Phase 2 trials for relapsed/refractory B-cell malignancies (search) and autoimmune diseases.
NX-2127, another oral BTK (search) degrader, is being evaluated in Phase 1a/1b trials for relapsed or refractory B-cell malignancies (search).
The company is also developing NX-1607, an oral CBL-B (search) inhibitor in Phase 1a/1b trials for immuno-oncology indications, and NX-0479/GS-6791 (search), an IRAK4 (search) degrader for rheumatoid arthritis (search).
Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Brisbane, California, is advancing a pipeline of small molecule and antibody therapies focused on targeted protein degradation and immuno-oncology. The company's most advanced programs center on Bruton's tyrosine kinase (BTK (search)) degraders for B-cell malignancies (search), with additional candidates targeting solid tumors and inflammatory diseases.
NX-5948: A Phase 2 BTK (search) Degrader
NX-5948, an orally bioavailable BTK (search) degrader, represents Nurix's lead clinical asset. The drug is currently in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies (search) and is also being explored for autoimmune disease indications. As a degrader rather than a traditional inhibitor, NX-5948 is designed to eliminate the BTK protein entirely, a mechanism that may offer advantages in overcoming resistance mutations that emerge with conventional BTK inhibitors.
NX-2127: Dual BTK (search) Degrader in Early Trials
NX-2127, another orally bioavailable BTK (search) degrader, is being evaluated in Phase 1a/1b clinical trials for relapsed or refractory B-cell malignancies (search). This dual-targeting approach aims to address the limitations of existing BTK-targeted therapies by degrading both wild-type and mutant forms of the kinase.
Expanding Beyond BTK (search): Immuno-Oncology and Inflammation
Beyond BTK (search) degradation, Nurix is developing NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B (search)) inhibitor, currently in Phase 1a/1b clinical trials for immuno-oncology indications. CBL-B inhibition represents a novel approach to enhancing anti-tumor immunity by removing a key intracellular checkpoint on T-cell activation.
In the inflammatory disease space, the company is advancing NX-0479/GS-6791 (search), an IRAK4 (search) degrader being developed for the treatment of rheumatoid arthritis (search) and other inflammatory conditions. This program underscores the potential of targeted protein degradation beyond oncology.
Strategic Collaborations
Nurix has established strategic collaboration agreements with several major pharmaceutical companies. These include partnerships with Gilead Sciences, Inc., Sanofi S.A. (search), and Pfizer Inc. for the co-development and co-commercialization of multiple drug candidates. These alliances provide both validation of Nurix's targeted protein degradation platform and resources to advance its pipeline.
Corporate Background
Originally incorporated in 2009 as Nurix Inc., the company rebranded to Nurix Therapeutics, Inc. in October 2018, reflecting its focused therapeutic mission. The company operates as a clinical-stage biopharmaceutical organization dedicated to discovering, developing, and commercializing therapies for cancer, inflammatory conditions, and other diseases.
As of June 26, 2026, Nurix Therapeutics held a market capitalization of $2.4 billion, with trailing 12-month revenue of $71.8 million. The company's stock had appreciated 97.07% over the prior year, reflecting investor confidence in its targeted protein degradation platform and advancing clinical pipeline.